SGTX
Price:
$22.47
Market Cap:
$56.22M
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has ...[Read more]
Industry
Biotechnology
IPO Date
2020-12-04
Stock Exchange
NASDAQ
Ticker
SGTX
According to Sigilon Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 42.21M. This represents a change of -77.93% compared to the average of 191.27M of the last 4 quarters.
The mean historical Enterprise Value of Sigilon Therapeutics, Inc. over the last ten years is 532.34M. The current 42.21M Enterprise Value has changed 692.96% with respect to the historical average. Over the past ten years (40 quarters), SGTX's Enterprise Value was at its highest in in the December 2020 quarter at 8.10B. The Enterprise Value was at its lowest in in the December 2019 quarter at -51015000.00.
Average
532.34M
Median
487.02M
Minimum
14.29M
Maximum
1.35B
Discovering the peaks and valleys of Sigilon Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 833.72%
Maximum Annual Enterprise Value = 1.35B
Minimum Annual Increase = -98.94%
Minimum Annual Enterprise Value = 14.29M
Year | Enterprise Value | Change |
---|---|---|
2022 | 133.44M | 833.72% |
2021 | 14.29M | -98.94% |
2020 | 1.35B | 97.71% |
2019 | 680.86M | 39.80% |
The current Enterprise Value of Sigilon Therapeutics, Inc. (SGTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
497.94M
5-year avg
532.34M
10-year avg
532.34M
Sigilon Therapeutics, Inc.’s Enterprise Value is greater than Reviva Pharmaceuticals Holdings, Inc. (33.37M), greater than ZyVersa Therapeutics, Inc. (2.53M), greater than Kiromic BioPharma, Inc. (13.48M), greater than Unicycive Therapeutics, Inc. (23.47M), less than Oncorus, Inc. (42.71M), greater than eFFECTOR Therapeutics, Inc. (4.74M), greater than Apollomics, Inc. (-11494787.00), greater than Angion Biomedica Corp. (22.43M), greater than Cardio Diagnostics Holdings, Inc. (9.47M), greater than Sonnet BioTherapeutics Holdings, Inc. (-907921.00), greater than X4 Pharmaceuticals, Inc. (38.44M), less than Landos Biopharma, Inc. (42.62M), greater than Apexigen, Inc. (-5121682.00), greater than Navidea Biopharmaceuticals, Inc. (-2504975.00), greater than NovaBay Pharmaceuticals, Inc. (3.81M), less than InMed Pharmaceuticals Inc. (631.55M), greater than GeoVax Labs, Inc. (19.24M), greater than Phio Pharmaceuticals Corp. (-2783607.00),
Company | Enterprise Value | Market cap |
---|---|---|
33.37M | $38.12M | |
2.53M | $2.65M | |
13.48M | $1.69M | |
23.47M | $55.01M | |
42.71M | $0 | |
4.74M | $941.00 | |
-11494787.00 | $9.98M | |
22.43M | $30.11M | |
9.47M | $10.73M | |
-907921.00 | $2.50M | |
38.44M | $57.64M | |
42.62M | $71.68M | |
-5121682.00 | $9.57M | |
-2504975.00 | $100.08K | |
3.81M | $3.33M | |
631.55M | $3.35M | |
19.24M | $27.84M | |
-2783607.00 | $2.61M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sigilon Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Sigilon Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Sigilon Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Sigilon Therapeutics, Inc. (SGTX)?
What is the 3-year average Enterprise Value for Sigilon Therapeutics, Inc. (SGTX)?
What is the 5-year average Enterprise Value for Sigilon Therapeutics, Inc. (SGTX)?
How does the current Enterprise Value for Sigilon Therapeutics, Inc. (SGTX) compare to its historical average?